MyoD is a Tumor Suppressor Gene in Medulloblastoma
Overview
Authors
Affiliations
While medulloblastoma, a pediatric tumor of the cerebellum, is characterized by aberrations in developmental pathways, the majority of genetic determinants remain unknown. An unbiased Sleeping Beauty transposon screen revealed MyoD as a putative medulloblastoma tumor suppressor. This was unexpected, as MyoD is a muscle differentiation factor and not previously known to be expressed in cerebellum or medulloblastoma. In response to deletion of one allele of MyoD, two other Sonic hedgehog-driven mouse medulloblastoma models showed accelerated tumor formation and death, confirming MyoD as a tumor suppressor in these models. In normal cerebellum, MyoD was expressed in the proliferating granule neuron progenitors that are thought to be precursors to medulloblastoma. Similar to some other tumor suppressors that are induced in cancer, MyoD was expressed in proliferating medulloblastoma cells in three mouse models and in human medulloblastoma cases. This suggests that although expression of MyoD in a proliferating tumor is insufficient to prevent tumor progression, its expression in the cerebellum hinders medulloblastoma genesis.
Wu F, Zhang J, Jiang Q, Li Q, Li F, Li J Cell Cycle. 2024; 23(5):573-587.
PMID: 38701194 PMC: 11135814. DOI: 10.1080/15384101.2024.2348344.
Cleveland A, Malawsky D, Churiwal M, Rodriguez C, Reed F, Schniederjan M Acta Neuropathol Commun. 2023; 11(1):8.
PMID: 36635771 PMC: 9838053. DOI: 10.1186/s40478-023-01508-x.
Development of Nystagmus With the Absence of MYOD Expression in the Extraocular Muscles.
Johnson L, Kueppers R, Shen E, Rudell J, McLoon L Invest Ophthalmol Vis Sci. 2021; 62(13):3.
PMID: 34617961 PMC: 8504190. DOI: 10.1167/iovs.62.13.3.
Ocasio J, Babcock B, Malawsky D, Weir S, Loo L, Simon J Nat Commun. 2019; 10(1):5829.
PMID: 31863004 PMC: 6925218. DOI: 10.1038/s41467-019-13657-6.
Principles of tumorigenesis and emerging molecular drivers of SHH-activated medulloblastomas.
Menyhart O, Gyorffy B Ann Clin Transl Neurol. 2019; 6(5):990-1005.
PMID: 31139698 PMC: 6529984. DOI: 10.1002/acn3.762.